Your browser doesn't support javascript.
loading
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
Tiberi, Simon; du Plessis, Nelita; Walzl, Gerhard; Vjecha, Michael J; Rao, Martin; Ntoumi, Francine; Mfinanga, Sayoki; Kapata, Nathan; Mwaba, Peter; McHugh, Timothy D; Ippolito, Giuseppe; Migliori, Giovanni Battista; Maeurer, Markus J; Zumla, Alimuddin.
Affiliation
  • Tiberi S; Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
  • du Plessis N; South African Department of Science and Technology, and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
  • Walzl G; South African Department of Science and Technology, and National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Stellenbosch University, Cape Town, South Africa.
  • Vjecha MJ; Veterans Affairs Medical Center, Washington, DC, USA.
  • Rao M; Champalimaud Foundation, Lisbon, Portugal; Krankenhaus Nordwest, Frankfurt, Germany.
  • Ntoumi F; Fondation Congolaise pour la Recherche Medicale, and Faculte des Sciences et Techniques, Universite M Ngouabi, Brazzaville, Republic of the Congo.
  • Mfinanga S; National Institute for Medical Research, Muhimbili Medical Research Centre, Dar es Salaam, Tanzania.
  • Kapata N; Institute of Public Health, Ministry of Health, Lusaka, Zambia.
  • Mwaba P; UNZA-UCLMS Research and Training Programme, and Apex University, Lusaka, Zambia.
  • McHugh TD; Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK.
  • Ippolito G; National Institute for Infectious Disease, L Spallanzani, Rome, Italy.
  • Migliori GB; World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Maugeri Care and Research Institute, Istituto di Ricovero e Cura a Carattere Sceintifico, Tradate, Italy.
  • Maeurer MJ; Champalimaud Foundation, Lisbon, Portugal; Krankenhaus Nordwest, Frankfurt, Germany.
  • Zumla A; Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK; National Institute of Health and Research Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: a.i.zumla@gmail.com.
Lancet Infect Dis ; 18(7): e183-e198, 2018 07.
Article in En | MEDLINE | ID: mdl-29580819
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Drug Therapy, Combination / Drug Development / Mycobacterium tuberculosis / Antitubercular Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2018 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberculosis / Drug Therapy, Combination / Drug Development / Mycobacterium tuberculosis / Antitubercular Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Lancet Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2018 Document type: Article Country of publication: United States